WPMS HTML Sitemap

Posts

• Lead article
• Oblique view
• 2002, Volume 09, Issue 01, pages 1-56
• Acute & Interventional Cardiology 2002; Volume 9: pages AIC 1- AIC 32
• Heart & Brain 2003; Volume 10, Issue 1: pages HB 1 - HN 24
• ACS management
• Cardiovascular Research 2018 Handbook
• CT coronary angiography with HeartFlow®
• News and views
• Opinion
• 2002, Volume 09, Issue 02, pages 57-124
• 2013, Volume 20 (online first)
• Acute & Interventional Cardiology 2003; Volume 10: pages AIC 1- AIC 88
• Lipids content
• Angiography
• Online First
• 2002, Volume 09, Issue 03, pages 125-184
• 2014, Volume 21 (online first)
• Acute & Interventional Cardiology 2004; Volume 11: pages AIC 1- AIC 104
• Angina book form
• Book review
• Angina
• Ad test
• 2002, Volume 09, Issue 04, pages 185-244
• 2002, Volume 09, Supplement 7: Early thrombolysis – the realities and the practicalities
• 2015, Volume 22 (online first)
• Acute & Interventional Cardiology 2005; Volume 12: pages AIC 1- AIC 104
• Correspondence
• Anticoagulation
• Acute and Interventional Cardiology
• 2002, Volume 09, Issue 05, pages 245-304
• 2002, Volume 09, Supplement 8: Management of acute coronary artery disease
• Acute & Interventional Cardiology 2006; Volume 13: pages AIC 1- AIC5 6
• Course review
• 2016, Volume 23 (online first)
• Diabetes and CVD
• diabetes
• 2002, Volume 09, Issue 06, pages 305-368
• 2003, Volume 10, Supplement 1: Diet and heart health: emerging evidence
• ECGs for the fainthearted
• 2017, Volume 24 (online first)
• Electrolytes
• Clinical articles
• 2002, Volume 09, Issue 07, pages 369-424
• 2003, Volume 10, Supplement 2: Socratic dialogue: the future management of hyperlipidaemia
• In brief
• Heart failure
• Editorials
• 2002, Volume 09, Issue 08, pages 425-492
• 2003, Volume 10, Supplement 3: Drug treatment of hypertension – the future is combination therapy
• Meeting report
• Heart valve disease
• Featured article
• 2002, Volume 09, Issue 09, pages 493-560
• 2003, Volume 10, Supplement 4: Phosphodiesterase type 5 (PDE5) inhibitors: looking beyond erectile dysfunction
• Lipids
• 2020, Volume 27, (online first)
• Heart and Brain
• Obesity
• 2002, Volume 09, Issue 10, pages 561-644
• 2004, Volume 11, Supplement 1: Diet and heart health symposium II
• Learning
• 2004, Volume 11, Supplement 2: Improved cardiovascular risk reduction: the evidence for raising HDL cholesterol
• Pulmonary hypertension
• Learning Articles
• Standalone learning with reflection modules
• 2004, Volume 11, Supplement 3: A new class in cholesterol management
• Supplements
• 2003, Volume 10, Issue 01, pages 1-76
• 2005, Volume 12, Supplement 1: This House believes that the UK healthcare system may be failing as many as 50% of patients with hyperlipidaemia by not reducing their cholesterol to effective levels
• 2003, Volume 10, Issue 02, pages 77-160
• 2005, Volume 12, Supplement 2: National Institute for Clinical Excellence (NICE) recommendations on the use of myocardial perfusion scintigraphy
• Books
• Videos
• 2003, Volume 10, Issue 03, pages 161-240
• 2006, Volume 13, Supplement 1: Switching statins: what are the issues and implications?
• Volumes
• 2003, Volume 10, Issue 04, pages 241-320
• 2006, Volume 13, Supplement 2: The role of angiotensin-converting enzyme inhibitors in coronary artery disease
• 2003, Volume 10, Issue 05, pages 321-400
• 2007, Volume 14, Supplement 1: Best practice principles for cholesterol lowering
• 2003, Volume 10, Issue 06, pages 401-488
• 2004, Volume 11, Issue 01, pages 1-80
• 2007, Volume 14, Supplement 3: Optimising global risk reduction: insights from REACH
• 2004, Volume 11, Issue 02, pages 81-168
• 2007, Volume 14, Supplement 4: Direct renin inhibition with aliskiren – a new option in treating hypertension
• 2004, Volume 11, Issue 03, pages 169-256
• 2008, Volume 15, Supplement 1: Clinical implications of the inhibition of the late sodium current: a new paradigm in the treatment of ischaemic heart disease
• 2004, Volume 11, Issue 04, pages 257-332
• 2008, Volume 15, Supplement 2: Cholesterol management
• 2004, Volume 11, Issue 05, pages 333-412
• 2009, Volume 16, Supplement 1: Moving forward in pulmonary arterial hypertension
• 2004, Volume 11, Issue 06, pages 413-496
• 2009, Volume 16, Supplement 2: Maximising safety and efficacy in the treatment of wet AMD
• 2005, Volume 12, Issue 01, pages 1-80
• 2009, Volume 16, Supplement 3: Multi-management of ischaemic heart disease: do we have the COURAGE of our convictions?
• 2005, Volume 12, Issue 02, pages 81-160
• 2010, Volume 17, Supplement 1: Aspirin – reassessing its role in cardiovascular disease
• 2005, Volume 12, Issue 03, pages 161-244
• 2010, Volume 17, Supplement 2: Are all angiotensin receptors blockers the same?
• 2005, Volume 12, Issue 04, pages 245-320
• 2010, Volume 17, Supplement 3: PCI in the UK – the continuing journey
• 2005, Volume 12, Issue 05, pages 321-404
• 2011, Volume 18, Supplement 1: Setting the standard for cardiac rehabilitation
• 2005, Volume 12, Issue 06, pages 405-476
• 2011, Volume 18, Supplement 2: Anaemia in chronic heart failure: what constitutes optimal investigation and treatment?
• 2006, Volume 13, Issue 01, pages 1-76
• 2011, Volume 18, Supplement 3: The management of stable angina – a perspective on recent guidance
• 2006, Volume 13, Issue 02, pages 77-156
• 2012, Volume 19, Supplement 1: Lipids and CVD: improving practice and clinical outcome
• 2006, Volume 13, Issue 03, pages 157-224
• 2012, Volume 19, Supplement 2: Chronic stable angina guidelines – is there an emerging international consensus?
• 2006, Volume 13, Issue 04, pages 225-300
• 2006, Volume 13, Issue 05, pages 301-372
• 2013, Volume 20, Supplement 1: Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice
• 2006, Volume 13, Issue 06, pages 373-440
• 2013, Volume 20, Supplement 2: Acute heart failure – a call to action
• 2007, Volume 14, Issue 01, pages 1-60
• 2013, Volume 20, Supplement 3: Cardiovascular health and disease prevention in clinical practice
• 2007, Volume 14, Issue 02, pages 61-120
• 2014, Volume 21, Supplement 1: Rivaroxaban in non-valvular atrial fibrillation: European experience
• 2007, Volume 14, Issue 03, pages 121-180
• 2014, Volume 21, Supplement 2: Unlocking the potential of NOACs
• 2007, Volume 14, Issue 04, pages 181-244
• 2015, Volume 22, Supplement 1: Pulmonary hypertension in UK clinical practice – an update
• 2007, Volume 14, Issue 05, pages 245-296
• 2016, Volume 23, Supplement 1: Perspectives in chronic heart failure – new treatment advances
• 2016, Volume 23, Supplement 2: The future of cardioversion management – new strategies for the use of oral anticoagulation in direct current cardioversion
• 2008, Volume 15, Issue 01, pages 1-56
• 2017, Volume 24, Supplement 1: Optimising the management of post-ACS patients
• 2008, Volume 15, Issue 02, pages 57-112
• 2018, Volume 25, Supplement 1: Anticoagulation in atrial fibrillation: focus on PIONEER AF-PCI and its implications
• 2008, Volume 15, Issue 03, pages 113-168
• 2018, Volume 25, Supplement 2: Management of cardiovascular disease in the patient with diabetes
• 2008, Volume 15, Issue 04, pages 169-216
• 2018, Volume 25, Supplement 3: Advances in cardiac pacing – A 60th anniversary update
• 2008, Volume 15, Issue 05, pages 217-272
• 2019, Volume 26, Supplement 1: Advances in the treatment of chronic heart failure with reduced ejection fraction in real-world settings
• 2008, Volume 15, Issue 06, pages 274-328
• 2009, Volume 16, Issue 01, pages 1-48
• 2019, Volume 26, Supplement 2: Edoxaban – insights from pivotal studies and sub-analyses
• 2009, Volume 16, Issue 02, pages 49-104
• 2020, Volume 27, Supplement 1: Peripheral artery disease in the UK – unmet needs
• 2009, Volume 16, Issue 03, pages 105-152
• 2020, Volume 27, Supplement 2: Adapting cardiovascular disease care to the ‘new norm’ of the COVID-19 era – same standard, different delivery
• 2009, Volume 16, Issue 04, pages 153-200
• 2009, Volume 16, Issue 05, pages 201-256
• 2009, Volume 16, Issue 06, pages 257-304
• 2010, Volume 17, Issue 01, pages 1-48
• 2010, Volume 17, Issue 02, pages 49-96
• 2010, Volume 17, Issue 03, pages 97-152
• 2010, Volume 17, Issue 04, pages 153-200
• 2010, Volume 17, Issue 05, pages 201-248
• 2010, Volume 17, Issue 06, pages 250-296
• 2011, Volume 18 Issue 01, pages 1-48
• 2011, Volume 18 Issue 02, pages 49-96
• 2011, Volume 18 Issue 03, pages 97-144
• 2011, Volume 18 Issue 04, pages 145-192
• 2011, Volume 18, Issue 5/6, pages 195-248
• 2012, Volume 19, Issue 1, pages 01-48
• 2012, Volume 19, Issue 2, pages 49-96
• 2012, Volume 19, Issue 3, pages 97-144
• 2012, Volume 19, Issue 4, pages 145-184
• 2013, Volume 20, Issue 1, pages 5-40
• 2013, Volume 20, Issue 2, pages 41-80
• 2013, Volume 20, Issue 3, pages 81-120
• 2013, Volume 20, Issue 4, pages 121-160
• 2014, Volume 21, Issue 1, pages 1–40
• 2014, Volume 21, Issue 2, pages 41–80
• 2014, Volume 21, Issue 3, pages 81–120
• 2014, Volume 21, Issue 4, pages 121–160
• 2015, Volume 22, Issue 1, pages 1–40
• 2015, Volume 22, Issue 2, pages 41–80
• 2015, Volume 22, Issue 3, pages 81–120
• 2015, Volume 22, Issue 4, pages 121–160
• 2016, Volume 23, Issue 1, pages 1–40
• 2016, Volume 23, Issue 2, pages 41–81
• 2016, Volume 23, Issue 3, pages 81–120
• 2016, Volume 23, Issue 4, pages 121–160
• 2017, Volume 24, Issue 1, pages 1–40
• 2017, Volume 24, Issue 2, pages 41–80
• 2017, Volume 24, Issue 3, pages 81–120
• 2017, Volume 24, Issue 4, pages 121–160
• 2018, Volume 25, Issue 1, pages 1–40
• 2018, Volume 25, Issue 2, pages 41–80
• 2018, Volume 25, Issue 3, pages 81–120
• 2018, Volume 25, Issue 4, pages 121–160
• 2019, Volume 26, Issue 1, pages 1–40
• 2019, Volume 26, Issue 2, pages 41–80
• 2019, Volume 26, Issue 3, pages 81–120
• 2019, Volume 26, Issue 4, pages 121–160
• 2020, Volume 27, Issue 1, pages 1–40
• 2020, Volume 27, Issue 2, pages 41–72
• 2020, Volume 27, Issue 3, pages 73–104
• 2020, Volume 27, Issue 4, pages 105–144